Collegiate will coordinate a panel of experts that will analyze data on adverse events reported after the application of the vaccine
The (National Health Surveillance Agency) established this Tuesday (June 16, 2026) a working group to further evaluate the safety of the dengue vaccine. 
According to , the new board is responsible for coordinating and providing technical support to the activities of a panel of experts, responsible for analyzing clinical data on adverse events reported after the application of the immunizer. Read (PDF – 110 KB).
According to the standard, the working group will work on evaluating additional information presented by the registration holder and consolidating data necessary to review the product’s risk and benefit profile.
The initiative was made in the context of continuous monitoring of vaccine safety, known as pharmacovigilance.
Composition
The group will be made up of representatives from different areas of Anvisa, including sectors responsible for biological products, pharmacovigilance, product monitoring and health inspection, in addition to the agency’s directors.
The National Immunization Program (PNI), from , is expected to participate as a guest in the activities.
The panel of experts will have a consultative nature and will be made up of professionals external to the agency, chosen based on criteria of technical qualification, professional experience and absence of conflict of interests. Participation will be voluntary and unpaid.
Decision
The ordinance establishes that the conclusions of the working group and panel of experts will serve as technical support for decisions by Anvisa’s Collegiate Board, responsible for final deliberations.
The group will have an indefinite duration and may remain active as long as there is a need for monitoring and analysis related to the safety of the vaccine.
This text was published by Agência Brasil, on June 16, 2026, at 9:09 am. The content is free for republication, the source is cited, and has been adapted to the standard of Poder360.
